InDevR Unveils OmniFlu HA To Streamline Influenza Vaccine Testing, Enhancing Market Speed

InDevR, Inc., a global leader in vaccine testing and multiplexed assay development, has launched OmniFlu HA, a validated kit for seasonal influenza vaccine manufacturers. This kit detects and quantifies hemagglutinin (HA) antigens, addressing the annual updates required by the World Health Organization's influenza strain recommendations.

OmniFlu HA offers simultaneous quantification of four seasonal HA antigens: A/H1, A/H3, B/Victoria, and B/Yamagata. InDevR’s portfolio also includes kits for quantifying neuraminidase (NA) proteins and nucleoproteins (NP), all tailored for the current flu season. This approach saves manufacturers months of development time.

Based on InDevR’s VaxArray® Platform and leveraging over 300 selected influenza antibodies, OmniFlu HA uses microarray-based multiplexed immunoassays to streamline vaccine characterization. This reduces validation bottlenecks and accelerates analytical development.

OmniFlu HA can analyze up to 64 samples with results in under two hours, compared to several days using manual ELISA or other immunoassays. It simplifies testing with an out-of-the-box solution optimized for seasonal influenza vaccine manufacturers.

InDevR’s expertise spans over 20 influenza seasons across more than a decade. "Through close partnerships with vaccine producers, we understand the unique challenges influenza vaccine development poses," said Kathy Rowen, Ph.D., CEO of InDevR. "OmniFlu HA is a flexible, efficient, and reliable solution that meets the industry's needs."

The OmniFlu HA microarray includes multiple antibodies targeting each vaccine component for comprehensive detection of influenza HA from various production systems. These include egg-based, cell-based, recombinant, and in vitro expressed protein systems applicable to mRNA vaccines.

Capture reagents are pre-validated for high specificity to the A/H1, A/H3, B/Victoria, and B/Yamagata components across every biannual strain recommendation by the World Health Organization.

VaxArray Platform

OmniFlu HA is part of a suite of kits designed for the VaxArray Platform. InDevR's benchtop instrument and ready-to-go kits allow vaccine developers to simplify and standardize workflows. The platform supports multiple stages of the process, from early development to clinical evaluation and potency testing.

"InDevR's technical expertise in establishing methods to quantify various viral agents using the VaxArray Platform has been invaluable," noted Dr. Raymond P. Goodrich from Colorado State University’s Research Innovation Center. "Streamlining processes and compressing project timelines has led to significant efficiency gains."

For more information about OmniFlu HA or its applications in vaccine production, visit indevr.com/omnifluha.